Orient Europharma Announces Agreement With Access for Canker Sores Treatment - Aphthasol(R) & OraDisc(TM)A

May 12, 2005, 01:00 ET from Access Pharmaceuticals, Inc.

    DALLAS, May 12 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
 (Amex:   AKC) today announced that it has entered into a Licensing and Supply
 Agreement with Orient Europharma (OEP). Under the terms of the Agreement, OEP
 will market Access' Aphthasol(R) paste & OraDisc(TM)A in six Asian
 territories: Taiwan, Hong Kong, Singapore, Malaysia, Philippines, and
 Thailand, and OEP will provide Access with an upfront licensing payment,
 milestone payments, and royalty payments on product sales.
     According to OEP, "These 2 products contain amlexanox, an active
 ingredient which is clinically-proven to accelerate healing and pain relief
 with no significant adverse effects.  OraDisc(TM)A patch is an improved
 delivery system for amlexanox.  The OraDisc(TM) technology is a proprietary
 mucoadhesive patch that gradually erodes and releases an active ingredient
 when applied to the inside of the mouth."  In addition to approval from FDA,
 Aphthasol(R) has also been approved for marketing in 10 European Union
 countries, Canada and Israel.
     Access Pharmaceuticals Inc. is an emerging pharmaceutical company focused
 on developing both novel low development risk product candidates and
 technologies with longer-term major product opportunities.  Access is also
 developing unique polymer platinates for use in the treatment of cancer and
 has an extensive portfolio of advanced drug delivery technologies including
 vitamin mediated targeted delivery, oral delivery, and nanoparticle
     This press release contains certain statements that are forward-looking
 within the meaning of Section 27a of the Securities Act of 1933, as amended,
 and that involve risks and uncertainties, including but not limited to
 statements made relating to projected product revenues, potential additional
 licensing arrangements, the amlexanox approval process, projections from our
 licensing partners for amlexanox sales, expected milestone payments, and the
 markets for amlexanox paste and OraDisc(TM) A. These statements are subject to
 numerous risks, including but not limited to the uncertainties associated with
 research and development activities, clinical trials, our ability to raise
 capital, the timing of and our ability to achieve regulatory approvals,
 dependence on others to market our licensed products, collaborations, future
 cash flow, the timing and receipt of licensing and milestone revenues,
 projected future revenue growth and our ability to generate near term
 revenues, the future success of the Company's marketed products Aphthasol(R)
 and products in development including polymer platinate, and OraDisc(TM), our
 ability to develop products from our platform technologies, our ability to
 manufacture amlexanox products in commercial quantities, our sales projections
 and the sales projections of our licensing partners, our ability to achieve
 licensing milestones and other risks detailed in the Company's Annual Report
 on Form 10-K for the year ended December 31, 2004, and other reports filed by
 us with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.